GBS German Bionic Systems GmbH

GBS German Bionic Systems GmbH develops advanced AI exoskeletons aimed at enhancing worker safety and ergonomics in various industries, facilitating lifting and carrying tasks while reducing physical strain. Founded in 2016, GBS German Bionic Systems GmbH is headquartered in Augsburg, Germany, and specializes in robotic exoskeleton technology. The company was co-founded by Armin Schmidt and Dirk Pöschl, with Schmidt serving as CEO. Since its inception, GBS has successfully completed three funding deals, culminating in a Series A funding round in December 2023, raising EUR 15 million, led by mubea.

This round also included contributions from investors such as Bayern Kapital and Benhamou Global Ventures. The company has not undergone any major strategic pivots since its establishment. German Bionic's primary offering is the Exia AI exoskeleton, designed to support lifting, lowering, walking, and carrying tasks in physically demanding environments. Exia provides up to 38 kg (84 lbs) of lifting assistance per movement, significantly alleviating strain on users during tasks such as lifting, carrying, and working in bent-over postures.

The product utilizes advanced AI and machine learning technologies to adapt to individual user movements in real-time, enhancing performance and reducing the risk of musculoskeletal disorders. Key sectors served include logistics, manufacturing, construction, and healthcare, with a focus on nursing and elderly care. German Bionic’s products are marketed primarily in Europe, North America, and select Asian markets, targeting a diverse client base comprising industrial workers, healthcare professionals, and companies looking to improve workplace ergonomics and safety. German Bionic generates revenue through direct sales of its flagship products, notably the Exia exoskeleton, alongside accompanying services such as the German Bionic Connect app and the German Bionic IO platform.

The company employs a business-to-business transaction model, engaging with various industries to provide tailored solutions for ergonomic support. Clients typically purchase Exia units, which include a subscription to ongoing AI-driven updates and analytics services that enhance operational efficiency. The pricing structure reflects the value provided through injury prevention and productivity improvements, making the exoskeleton an essential investment for businesses aiming to reduce sick days and improve employee wellbeing. In December 2023, GBS German Bionic Systems GmbH raised EUR 15 million in a Series A extension round of funding led by mubea, with support from existing investors.

This funding will be utilized to meet the demand for smart occupational safety systems. The company is focused on expanding its product offerings with new enhancements to the Exia exoskeleton and plans to enter additional markets in Asia and North America by 2025, targeting industries that prioritize ergonomic solutions.